Results 271 to 280 of about 387,869 (336)
2025 ACVIM Forum Research Abstract Program
Journal of Veterinary Internal Medicine, Volume 39, Issue 6, November/December 2025.
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update
Expert Review of Vaccines, 2021Introduction: HEPLISAV-B is a hepatitis B vaccine composed of rHBsAg mixed with a synthetic oligonucleotide containing CpG motifs that stimulate innate immunity through TLR9.
G. Lee, S. Lim
semanticscholar +1 more source
Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant
The Annals of Pharmacotherapy, 2020Objective: To review the immunogenicity and safety of a hepatitis B vaccine containing the cytosine phosphoguanosine (CpG) 1018 adjuvant (HepB-CpG). Data Sources: Literature searches were performed using PubMed and Scopus with the search terms hepatitis ...
Caroline R. Champion
semanticscholar +1 more source
Clinics in Liver Disease, 2004
Immunization is the most effective way to prevent transmission of HBV and, hence, the development of acute or chronic hepatitis B. The national strategy to eliminate transmission of the virus in the United States includes vaccination of all newborn infants, children, adolescents, and high-risk adults.
Emmet B. Keeffe +3 more
openaire +5 more sources
Immunization is the most effective way to prevent transmission of HBV and, hence, the development of acute or chronic hepatitis B. The national strategy to eliminate transmission of the virus in the United States includes vaccination of all newborn infants, children, adolescents, and high-risk adults.
Emmet B. Keeffe +3 more
openaire +5 more sources
Nature, 1976 The high rate of infection with hepatitis B virus in certain defined populations in industralized countries and among the general population in many non-industrialized countries stresses the need for hepatitis B vaccines. Hepatitis B, one of at least six different forms of viral hepatitis, may progress to chronic liver disease, including chronic ...
openaire +3 more sources
Journal of Virological Methods, 1985
As hepatitis B virus does not replicate in tissue culture systems, it was impossible to prepare a vaccine in the conventional way. However, the surface-antigen of the virus is present in abundance in the blood of certain virus carriers. This phenomenon has been used to develop plasma-derived hepatitis B vaccines and these vaccines are now available. In
openaire +6 more sources
As hepatitis B virus does not replicate in tissue culture systems, it was impossible to prepare a vaccine in the conventional way. However, the surface-antigen of the virus is present in abundance in the blood of certain virus carriers. This phenomenon has been used to develop plasma-derived hepatitis B vaccines and these vaccines are now available. In
openaire +6 more sources
Journal of Hepatology, 2003
Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
openaire +3 more sources
Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
openaire +3 more sources
Vaccine, 2003
The status and likely impact of existing and potential new combined hepatitis B vaccines were broadly considered at the Viral Hepatitis Prevention Board (VHPB) meeting in Malta, October 2001. The currently available and/or licensed combined hepatitis B vaccines in Europe and the prospects for further such vaccines were reviewed.
FitzSimons, D. +3 more
openaire +4 more sources
The status and likely impact of existing and potential new combined hepatitis B vaccines were broadly considered at the Viral Hepatitis Prevention Board (VHPB) meeting in Malta, October 2001. The currently available and/or licensed combined hepatitis B vaccines in Europe and the prospects for further such vaccines were reviewed.
FitzSimons, D. +3 more
openaire +4 more sources